Funding for this research was provided by:
Canadian Institutes of Health Research (950-231837)
Received: 21 September 2020
Accepted: 10 November 2020
First Online: 27 November 2020
Ethics approval and consent to participate
: All animal experiments were approved by the Maisonneuve Rosemont Hospital Animal Care Committee and were performed in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Visual Research.
: Not applicable.
: The corresponding author (SC) holds a patent on a small peptide antagonist of IL-1R, which could be useful in inflammatory ischemic retinopathies, yet this compound remains at the pre-clinical stage and the intellectual property is held by the CHU-Sainte Justine Hospital, Montreal.